Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. Mountzios G, et al. Among authors: kosmidis p. Clin Lung Cancer. 2021 Mar;22(2):e180-e192. doi: 10.1016/j.cllc.2020.09.017. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33162330
Advanced NSCLC: new cytostatic agents.
Kosmidis PA, Manegold C. Kosmidis PA, et al. Lung Cancer. 2003 Aug;41 Suppl 1:S123-32. doi: 10.1016/s0169-5002(03)00156-9. Lung Cancer. 2003. PMID: 12867071 Review.
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S. Linardou H, et al. Among authors: kosmidis p. Lancet Oncol. 2008 Oct;9(10):962-72. doi: 10.1016/S1470-2045(08)70206-7. Epub 2008 Sep 17. Lancet Oncol. 2008. PMID: 18804418 Review.
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, Dimopoulos AM. Bafaloukos D, et al. Among authors: kosmidis p. BMC Med. 2010 Jan 7;8:3. doi: 10.1186/1741-7015-8-3. BMC Med. 2010. PMID: 20055981 Free PMC article. Clinical Trial.
All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer.
Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos D, Kosmidis P, Murray S. Linardou H, et al. Among authors: kosmidis p. Cancer Treat Rev. 2011 May;37(3):221-33. doi: 10.1016/j.ctrv.2010.07.008. Epub 2010 Sep 29. Cancer Treat Rev. 2011. PMID: 20817364 Review.
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Economopoulou P, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G. Psyrri A, et al. Among authors: kosmidis p. J Transl Med. 2017 Feb 13;15(1):30. doi: 10.1186/s12967-017-1134-7. J Transl Med. 2017. PMID: 28193231 Free PMC article. Clinical Trial.
264 results